Programme 14 February
08:30–09:15
Morning coffee meeting: Trends and Needs in Clinical Trials – Opportunities or Barriers for Norway?
In this meeting we address the major trends in clinical trials and discuss if this is an opportunity or a barrier for Norway to be competitive in attracting more clinical trials. Go to programme
09:30–10:30
Bridging the gap between academia and industry
Turning life science inventions into lifesaving products or solutions for the health and care sector is a long and challenging path. To succeed, critical components of the system, research universities, academic hospitals, biotechnology companies (large and small), and venture capital – must work together.
Introduction by
- Christine Wergeland S?rbye CEO, Oslo Science City
Panel discussion
- Hilde Nebb Innovation director and Professor, UiO Growth House
- Per Morten Sandset Vice-Rector for Research and Innovation, UiO and Leader, Health&Care Advisory Board / R?det for HelseOmsorg21
- Bj?rn Atle Bj?rnbeth CEO, Oslo University Hospital
- Ole Kristian Hjelstuen CEO, Inven2
- Kristin Willoch Haugen, Director Regional Office Oslo Viken, Innovation Norway
- Alan Cuthbertson, Head of Radiopharmaceuticals Research, Bayer
Moderator: Frode Nakkim, Communications Manager, Bayer
More speakers to be announced
All day event
Partnership for Life - Matchmaking Meetings
One-to-one matchmaking meetings which aims to match global pharma investors/partners with academic research groups and start-ups. To participate, you need to create a personal profile in Brella. How to create your personal profile
10:30–11:00 Break
11:00–12:30
12:30–13:30 Lunch
13:30–15:00
Young Talents
Network meetings
You will have the opportunity to meet representatives from companies. Remember to register beforehand.
Pitching Session
- Thelper, Katja Vetvik, Founder
- Tribune Therapeutics, Georg Vo Beiske, CEO
- Development of a new product to relieve the symptoms of dry mouth, Marianne Hiorth, Department of Pharmacy, UiO
- Oncosyne, Peter W. Eide, Cofounder & CTO
- Kongsberg Beam Technology, Stephan Dymling, CTO
- p95HER2-CAR T cell targeting metastatic breast cancer on-Target, but no off-Tumor, Esmaeil Dorraji, Institute for Cancer Research, Radium Hospital, Oslo University Hospital
- Zyberia AS, Jonas Carsten Jeppesen, CEO
- Metabolism-on-chip, Mathias Busek, Postdoctor, Hybrid Technology Hub, Center of Excellence, UiO,
Panel:
-
Jan B?rge Jakobsen, CEO, Bayer Norway
-
P?l Hasvold, Medical Evidence Head AstraZeneca
-
Andre Breg?rd, General Manager & Vice President, Novo Nordisk Norway
Host: Morten Egeberg, Leader SPARK Norway and Administrative Leader UiO:Life Science